Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Status:
Completed
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and
efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with
Cushing's disease.